PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism

Peroxisome proliferator activated receptor gamma 2 (PPARg2) is the nutritionally regulated isoform of PPARg. Ablation of PPARg2 in the ob/ob background, PPARg2−/− Lepob/Lepob (POKO mouse), resulted in decreased fat mass, severe insulin resistance, β-cell failure, and dyslipidaemia. Our results indicate that the PPARg2 isoform plays an important role, mediating adipose tissue expansion in response to positive energy balance. Lipidomic analyses suggest that PPARg2 plays an important antilipotoxic role when induced ectopically in liver and muscle by facilitating deposition of fat as relatively harmless triacylglycerol species and thus preventing accumulation of reactive lipid species. Our data also indicate that PPARg2 may be required for the β-cell hypertrophic adaptive response to insulin resistance. In summary, the PPARg2 isoform prevents lipotoxicity by (a) promoting adipose tissue expansion, (b) increasing the lipid-buffering capacity of peripheral organs, and (c) facilitating the adaptive proliferative response of β-cells to insulin resistance.

[1]  Guillaume Adelmant,et al.  Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1 , 2001, Nature.

[2]  Bruce M. Spiegelman,et al.  Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction , 2003, Nature.

[3]  B. Spiegelman,et al.  Molecular regulation of adipogenesis. , 2000, Annual review of cell and developmental biology.

[4]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[5]  Joseph L Evans,et al.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. , 2002, Endocrine reviews.

[6]  K P Hummel,et al.  Diabetes, a New Mutafton in the Mouse , 1966, Science.

[7]  R. Unger.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0870 Minireview: Weapons of Lean Body Mass Destruction: The Role of Ectopic Lipids in the Metabolic Syndrome , 2022 .

[8]  Marc Montminy,et al.  CREB regulates hepatic gluconeogenesis through the coactivator PGC-1 , 2001, Nature.

[9]  L. Orci,et al.  Lipoapoptosis: its mechanism and its diseases. , 2002, Biochimica et biophysica acta.

[10]  B. Spiegelman,et al.  Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity. , 1993, Genes & development.

[11]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[12]  S. Makino,et al.  Genetic typing of the mouse ob mutation by PCR and restriction enzyme analysis. , 1997, Experimental animals.

[13]  A. Wolffe,et al.  PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis , 2002 .

[14]  B. Spiegelman,et al.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. , 1999, Molecular cell.

[15]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[16]  W. Lieberthal,et al.  Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether. , 1999, The Biochemical journal.

[17]  I. G. Fantus,et al.  N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. , 2003, American journal of physiology. Endocrinology and metabolism.

[18]  A. Wolffe,et al.  PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. , 2002, Genes & development.

[19]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[20]  S. Kersten,et al.  Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. , 2006, Endocrinology.

[21]  M. Fu,et al.  Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity , 2004 .

[22]  M. Orešič,et al.  Metabolomic approaches to phenotype characterization and applications to complex diseases , 2006, Expert review of molecular diagnostics.

[23]  M. Olive,et al.  Life without white fat: a transgenic mouse. , 1998, Genes & development.

[24]  P. Pekala,et al.  Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[25]  B. Spiegelman,et al.  Targeted Elimination of Peroxisome Proliferator-Activated Receptor γ in β Cells Leads to Abnormalities in Islet Mass without Compromising Glucose Homeostasis , 2003, Molecular and Cellular Biology.

[26]  A. Aljada,et al.  Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.

[27]  Tatsuhiko Kodama,et al.  Lysophosphatidylcholine Enhances Cytokine Production of Endothelial Cells via Induction of L-Type Amino Acid Transporter 1 and Cell Surface Antigen 4F2 , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[28]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[29]  W. Dröge,et al.  Effect of thiol antioxidant on body fat and insulin reactivity , 2004, Journal of Molecular Medicine.

[30]  D. Vance,et al.  The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. , 1988, The Journal of biological chemistry.

[31]  R. Hammer,et al.  Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. , 1998, Genes & development.

[32]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[33]  B. Spiegelman,et al.  Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. , 1996, The Journal of clinical investigation.

[34]  B. Spiegelman,et al.  Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. , 2003, The Journal of clinical investigation.

[35]  B. Spiegelman,et al.  Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. , 2003, Molecular and cellular biology.

[36]  N. Bashan,et al.  Proposed mechanisms for the induction of insulin resistance by oxidative stress. , 2005, Antioxidants & redox signaling.

[37]  W. Wahli,et al.  Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. , 1996, Endocrinology.

[38]  M. Kasuga,et al.  The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. , 2001, Diabetes.

[39]  M Elia,et al.  Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. , 1992, World review of nutrition and dietetics.

[40]  B. Brewer,et al.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. , 2003, The Journal of clinical investigation.

[41]  J. Auwerx,et al.  Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. O’Rahilly,et al.  Leptin Deficiency Unmasks the Deleterious Effects of Impaired Peroxisome Proliferator–Activated Receptor γ Function (P465L PPARγ) in Mice , 2006, Diabetes.

[43]  Matej Oresic,et al.  The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. , 2005, Diabetes.

[44]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[45]  W. Wahli,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rat PPARs: Quantitative Analysis in Adult Rat Tissues and Regulation in Fasting and Refeeding , 2022 .

[46]  J. McGarry.  Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[47]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[48]  Weimin He,et al.  Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Y. Terauchi,et al.  Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. , 2004, Diabetes.

[50]  V. Mootha,et al.  Energy Metabolism in Uncoupling Protein 3 Gene Knockout Mice* , 2000, The Journal of Biological Chemistry.

[51]  Douglas L. Coleman.  The influence of genetic background on the expression of mutations at the diabetes (db) locus in the mouse. VI: Hepatic malic enzyme activity is associated with diabetes severity. , 1992, Metabolism: Clinical and Experimental.

[52]  U. Boggi,et al.  Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. , 2002, Diabetes.

[53]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[54]  J. H. Johnson,et al.  Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. Cooney,et al.  The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[56]  S. O’Rahilly,et al.  Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. , 2006, Diabetes.

[57]  C. Lelliott,et al.  Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation , 2004, International Journal of Obesity.

[58]  L. Philipson,et al.  Reactive species and early manifestation of insulin resistance in type 2 diabetes , 2006, Diabetes, obesity & metabolism.

[59]  Weimin He,et al.  Muscle-specific Pparg deletion causes insulin resistance , 2003, Nature Medicine.

[60]  J. Flier,et al.  Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. , 1997, The Journal of biological chemistry.

[61]  J. Auwerx,et al.  Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. , 2000, Diabetologia.

[62]  R. Vigneri,et al.  Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. , 2002, Diabetes.

[63]  Matej Oresic,et al.  Processing methods for differential analysis of LC/MS profile data , 2005, BMC Bioinformatics.

[64]  Jerry Donovan,et al.  Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. , 2003, Nature.

[65]  R. Østerby,et al.  Optimizing sampling efficiency of stereological studies in biology: or ‘Do more less well!‘ , 1981, Journal of microscopy.